CNTA 240517 22.50P (CNTA240517P22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

CNTA240517P22500

Watchlist

13.20
0.000.00%

15min DelayClose May 15 15:59 ET

0.00High0.00Low

Intraday

News

Centessa Pharmaceuticals | 10-Q: Quarterly report
SEC announcementMay 13 16:36 ET · Announcements
Centessa Pharmaceuticals 1Q Loss/Shr 38c >CNTA
Centessa Pharmaceuticals 1Q Loss/Shr 38c >CNTA
Dow JonesMay 13 16:20 ET
Press Release: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 -- Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of Serp
Dow JonesMay 13 16:10 ET
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Wednesday's premarket activity, as earnings continue t
MT NewswiresApr 24 07:53 ET
Express News | Reported Earlier, Centessa Pharmaceuticals Prices $100M Public Offering Of 10,810,810 American Depositary Shares At $9.25/ADS
Moomoo 24/7Apr 24 02:18 ET
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering
Centessa Pharmaceuticals (CNTA) said Tuesday it is seeking to raise $100 million from an underwritten public offering of American Depositary Shares, each representing one ordinary share. The proposed
MT NewswiresApr 23 18:00 ET

Comments

Trytosaveabit

Apr 23 15:37

Update

$Centessa Pharmaceuticals(CNTA.US)$ Press Release: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Dow Jones· 15 mins ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for p...

Trytosaveabit

Apr 22 06:10

Update

$Centessa Pharmaceuticals(CNTA.US)$ The FDA Has Cleared Centessa Pharmaceuticals' Investigational New Drug Application To Initiate A Phase 1 First-in-human, Clinical Trial Of ORX750 For Narcolepsy

Meltyy

Apr 2 22:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

JESSE JAMES8832

Feb 10 10:15

buy

$Centessa Pharmaceuticals(CNTA.US)$

Trytosaveabit

Dec 10, 2023 12:04

Update

$Centessa Pharmaceuticals(CNTA.US)$ BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously...